Moderna, Analysts

Moderna Analysts Lift Price Targets Without Budging on Ratings as Index Entry Looms

Published on 11/17/2026 at 17:11 | Editorial boerse-global.de
JPMorgan lifted its Moderna target to $102 and Morgan Stanley to $200, but both kept their ratings unchanged despite an earnings beat and melanoma data.
Moderna Analysts Lift Price Targets Without Budging on Ratings as Index Entry Looms Illustration mit AI erstellt.

Two of Wall Street's most closely watched research desks raised their price targets on Moderna on the same day — and neither one moved an inch on its rating. JPMorgan lifted its target to $102 from $77 while keeping an Underweight stance, and Morgan Stanley pushed its own mark to $200 from $95, reaffirming Equal Weight. The gap between the two figures says plenty about how much room analysts see for disagreement on valuation, but the message from both is the same: brighter prospects do not automatically add up to a buy.

At JPMorgan, analyst Jessica Fye acknowledged the improved financial and clinical picture, including heavier spending on oncology, yet the firm still considers the stock too expensive. Morgan Stanley's far more aggressive revision likewise stops short of a positive call. Investors would do well to separate a higher target from an actual endorsement of the shares.

A clinical catalyst with a moving date

The next potential share-price driver, according to JPMorgan, is interim data from the randomized Phase II trial of Intismeran in adjuvant renal cell carcinoma. Those results could land in late 2026 or early 2027, though the timing has not been fixed. Such data would amount to a further clinical test following Intismeran's first Phase III success, helping to frame the drug candidate's prospects beyond the setting already studied. A favorable outcome is anything but assured.

Moderna laid out the melanoma findings at its analyst day on Thursday. In high-risk melanoma, Intismeran combined with Keytruda cut the risk of recurrence or death by 42%, while the risk of distant metastasis or death fell by 38%. Those gains help explain why oncology now carries more weight in the company's investment plans — though they do not substitute for proof that other trials will fare equally well.

Should investors sell immediately? Or is it worth buying Moderna?

Earnings beat meets a valuation debate

Operationally, Moderna has also been running ahead of expectations. In the most recently reported quarter, earnings per share came in at $0.38 against a forecast loss of $1.10 per share. Revenue for the period reached $1.31 billion, well above the $890.25 million consensus, marking growth of 29.2% from the year-earlier quarter. The surprise lends support to the case for a business recovery, but the investment question still hinges on how durable that improvement proves and how much of it the valuation already reflects.

The third-quarter 2026 figures, published on November 6, showed revenue of $1.3 billion and net income of $0.2 billion under US accounting standards. Diluted earnings per share were $0.38, according to company statements. Moderna expects its cash position to land between $8.1 billion and $8.3 billion at the end of 2026 — a projection distinct from the quarterly result already on the books.

Index seat confirmed, sell-off explained elsewhere

MSCI announced on November 11 that Moderna will join the MSCI World Index, with the change set to take effect after the close on November 30, 2026. The confirmed index switch is seen as a possible spur to additional demand for the stock.

That announcement, however, was not the trigger behind the recent share-price losses. According to Reuters, Thursday's weakness stemmed instead from disappointment over the absence of a near-term roadmap for the coming fiscal year, compounded by profit-taking after the analyst day news. Moderna presented its growth strategy at that event but held back a revenue forecast for 2027; a formal financial outlook for that year is due when the company reports fourth-quarter 2026 results.

Moderna at a turning point? This analysis reveals what investors need to know now.

Vaccine data round out the picture

Alongside the financial numbers, Moderna announced on November 11 a publication concerning its mNEXSPIKE vaccine in the journal JAMA Network Open. The study examines comparative effectiveness under real-world conditions in adults aged 65 and older. It adds real-world evidence to the clinical news flow — comparative effectiveness data rather than a mere announcement of further research.

Taken together, the higher targets rest on both operational momentum and clinical wins. The unchanged ratings, though, draw a firm line: in the eyes of both firms, better prospects alone do not yet make Moderna a stock to buy.

Ad

Moderna Stock: New Analysis - 17 November

Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Moderna analysis...

Disclaimer...
en | US60770K1079 | MODERNA | boerse | 70527807 |